// App-Quantinova.ai

8541.0 : DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.

Researchers

Presenter

  • Adam D. Cohen

Principal Investigators

  • Suzanne Trudel

  • Sagar Lonial

  • Edward N. Libby

  • Hans Chulhee Lee

  • Britta Besemer

  • Thierry Facon

  • Ajay K. Nooka

  • Natalie Scott Callander

  • Ajai Chari

  • Ira Gupta

  • Sofia Paul

  • Joanna Opalinska

  • Paul G. Richardson

Medical Centers

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Emory University, Winship Cancer Institute, Atlanta, GA

  • Division of Medical Oncology, University of Washington, Seattle, WA

  • 1.MD Anderson Cancer Center, Houston, TX

  • Universitts-Frauenklinik Tubingen, Tubingen, Germany

  • Hopital Claude Huriez, Lille, France

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • GlaxoSmithKline, Upper Providence, PA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Hormone receptor

Drug/Treatment

  • GSK2857916

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03525678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved